Back to search
FDAFDA · Food and drugs·Recall number D-0555-2026

Duloxetine DR Capsules, 30 mg, 30 count bottles, Rx, Relabeled by: Enovachem Pharmaceuticals, Torrance, CA 90501, NDC 76420-634-30, Marketed by: Ajanta Pharma USA Inc.

Published June 10, 2026 · Recall initiated: May 14, 2026

Summary

FDA records drug Class II recall D-0555-2026, published June 10, 2026 and initiated May 14, 2026. Recalling firm: Asclemed USA Inc.; Status: Ongoing; Reported quantity: 50 bottles; Lot: Lot # 050725G-30 & 050725F-30, Exp Date: 06/30/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit.

What to do

Voluntary: Firm initiated · Letter

Get an email if DULOXETINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DULOXETINE
Manufacturer
Asclemed USA Inc.
Distributor
US Nationwide.
Lot
Lot # 050725G-30 & 050725F-30, Exp Date: 06/30/2026
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Duloxetine DR Capsules, 30 mg, 30 count bottles, Rx, Relabeled by: Enovachem Pharmaceuticals, Torrance, CA 90501, NDC 76420-634-30, Marketed by: Ajanta Pharma USA Inc. recalled?

Yes. FDA published recall D-0555-2026 on June 10, 2026. Reported hazard: CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DULOXETINE.